Acer Therapeutics has announced both a corporate restructuring and update on its pipeline programs. Acer’s headcount has been reduced from 48 to 19 employees and pre-commercial activities of EDSIVO™ (celiprolol) have been halted. The restructuring is expected to provide the resources needed for Acer to conduct its planned business operations through 2020. Acer intends to pursue discussions with the U.S. FDA regarding its previously announced Complete Response Letter (CRL) for Acer’s New Drug Application (NDA) for EDSIVO™ and to continue the development of Acer’s additional pipeline programs, including ACER-001 and osanetant. Learn More